The meeting will be held in Seattle, Washington from May 1-5 at the Washington State Convention Center.
"Allergan is pleased to be presenting data at ARVO this year," EVP and President of Global R&D Brands David Nicholson said. "With more than 60 years of eye care experience and 17 mid-to-late stage programs in development, Allergan is committed to advancing research and products for the eye care community."
The 18 presentations range from studies on self-reported vision impairment in nursing home residents, to comparisons of gel-type artificial tears, to glaucoma therapies. The data is grouped into three categories: retina, ocular surface and glaucoma studies.
Allergan is a global leader in eye care products and medications. It also markets treatments for a wide range of other health-related conditions, including the cardiovascular system, central nervous system, urology and women's health. It is focused on developing and manufacturing prescription and generic drugs, biologics and over-the-counter medications. Allergan conducts commercial operations in approximately 100 countries.